POLYENDOCRINE METABOLIC OVARIAN SYNDROME (PMOS): A GLOBAL CONSENSUS PROCESS AND SCIENTIFIC REDEFINITION
DOI:
https://doi.org/10.63330/aurumpub.044-028Keywords:
Scientific evidence, Pathophysiology, Clinical management, Quality of life, Women’s healthAbstract
The present study is characterized as a narrative literature review, of a descriptive, analytical, and interpretative nature, whose objective was to discuss and problematize the available scientific knowledge regarding the redefinition of Polycystic Ovary Syndrome (PCOS) into Polyendocrine Metabolic Ovarian Syndrome (PMOS). Considering the high global prevalence of the condition and its clinical, metabolic, reproductive, and psychosocial impacts, the study sought to understand how the change in nomenclature may contribute to greater diagnostic accuracy, reduction of stigma, and improvement of care practices. To this end, sources were selected from recognized scientific databases, including articles, systematic reviews, international guidelines, technical reports, and complementary documents, prioritizing studies published between 2022 and 2026. The analysis allowed the identification of recurring categories, such as diagnostic criteria, clinical and metabolic outcomes, therapeutic strategies, and social participation in the consensus process. Convergence was observed regarding the need for more inclusive criteria, while divergences emerged in therapeutic approaches, highlighting both the use of pharmacological agents and bariatric surgery. The discussion revealed practical implications for clinical practice and theoretical implications for research, emphasizing the importance of interdisciplinarity and the integration between science and society. It is concluded that the redefinition of PCOS to PMOS represents a significant advancement, but still requires multicenter studies, economic analyses in different contexts, and greater community involvement, establishing itself as a fertile field for future investigations and for the consolidation of a global scientific consensus.
Downloads
References
BAHRI KHOMAMI, M. et al. Systematic review and meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Nature Communications, v. 15, n. 1, art. 5591, 2024.
BIZUNEH, A. D. et al. The PCOS phenotype in unselected populations study: ethnic variation in population-based normative cut-offs for defining hirsutism. European Journal of Endocrinology, v. 192, n. 3, p. 228-239, 2025.
BIZUNEH, A. D. et al. Evaluating the diagnostic accuracy of androgen measurement in polycystic ovary syndrome: a systematic review and diagnostic meta-analysis to inform evidence-based guidelines. Human Reproduction Update, v. 31, n. 1, p. 48-63, 2025.
COHUT, M. From PCOS to PMOS: how this name change is set to improve care. Medical News Today, 13 maio 2026. Disponível em: <https://www.medicalnewstoday.com/articles/pcos-to-pmos-how-name-change-set-to-improve-care>.
DOBBIE, L. J. et al. Childhood, adolescent, and adulthood adiposity are associated with risk of PCOS: a Mendelian randomization study with meta-analysis. Human Reproduction, v. 38, n. 6, p. 1168-1182, 2023.
ENDOCRINE SOCIETY. Polyendocrine metabolic ovarian syndrome: new name to improve diagnosis and care of condition affecting 170 million women worldwide. Washington, DC, 12 maio 2026. Disponível em: <https://www.endocrine.org/news-and-advocacy/news-room/2026/pcos-name-change>.
GOLDBERG, A. et al. Anti‐obesity pharmacological agents for polycystic ovary syndrome: a systematic review and meta‐analysis to inform the 2023 international evidence‐based guideline. Obesity Reviews, v. 25, n. 5, art. e13704, 2024.
JOHAM, A. E. et al. Polycystic ovary syndrome. The Lancet Diabetes & Endocrinology, v. 10, n. 9, p. 668-680, 2022.
JOHAM, A. E.; TEEDE, H. J. PCOS – a metabolic condition with health impacts on women and men. Nature Reviews Endocrinology, v. 18, n. 4, p. 197-198, 2022.
LI, S. et al. Bariatric surgery impact on women with polycystic ovary syndrome: a prospective cohort study. Research, v. 8, art. 0664, 2025.
MOUSA, A.; TAY, C. T.; TEEDE, H. Technical report for the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Australia: Monash University, 2023.
NEVEN, A. C. H. et al. Prevalence of polycystic ovary syndrome: a global and regional systematic review and meta-analysis. Human Reproduction Update, v. 32, n. 3, p. 277-312, 2026.
NG, A. H. et al. Consumer and community involvement: implementation research for impact (CCIRI) – implementing evidence-based patient and public involvement across health and medical research in Australia – a mixed methods protocol. Health Research Policy and Systems, v. 23, n. 1, art. 25, 2025.
NORMAN, R. J.; MORMAN, R.; TEEDE, H. J. “Tis but thy name that is my enemy” – the problem with the naming of polycystic ovary syndrome. Fertility and Sterility, v. 120, n. 2, p. 249-250, 2023.
PEA, J. et al. Ultrasonographic criteria in the diagnosis of polycystic ovary syndrome: a systematic review and diagnostic meta-analysis. Human Reproduction Update, v. 30, n. 1, p. 109-130, 2024.
PEÑA, A. S. et al. International evidence-based recommendations for polycystic ovary syndrome in adolescents. BMC Medicine, v. 23, n. 1, art. 151, 2025.
PILTONEN, T. T. et al. Ovarian cysts in polycystic ovary syndrome. JAMA Internal Medicine, 2026.
RIESTENBERG, C. et al. Health care-related economic burden of polycystic ovary syndrome in the United States: pregnancy-related and long-term health consequences. The Journal of Clinical Endocrinology & Metabolism, v. 107, n. 2, p. 575-585, 2022.
SAMARASINGHE, S. N. S. et al. Bariatric surgery for spontaneous ovulation in women living with polycystic ovary syndrome: the BAMBINI multicentre, open-label, randomised controlled trial. The Lancet, v. 403, n. 10443, p. 2489-2503, 2024.
SU, P.; CHEN, C.; SUN, Y. Physiopathology of polycystic ovary syndrome in endocrinology, metabolism and inflammation. Journal of Ovarian Research, v. 18, n. 1, art. 34, 2025.
TAY, C. T. et al. 2023 International evidence‐based polycystic ovary syndrome guideline update: insights from a systematic review and meta‐analysis on elevated clinical cardiovascular disease in polycystic ovary syndrome. Journal of the American Heart Association, v. 13, n. 16, art. e033572, 2024.
TEEDE, H. J. et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. The Lancet, art. S0140673626007178, 2026.
TEEDE, H. J. et al. Polycystic ovary syndrome perspectives from patients and health professionals on clinical features, current name, and renaming: a longitudinal international online survey. eClinicalMedicine, v. 84, art. 103287, 2025.
TEEDE, H. J. et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. European Journal of Endocrinology, v. 189, n. 2, p. G43-G64, 2023.
ZHAO, H. et al. Multi-ancestry genome-wide association analyses of polycystic ovary syndrome. Nature Genetics, v. 57, n. 11, p. 2669-2681, 2025.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
